Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Immunotherapy has been incorporated into the first- and second-line treatment strategies for non-small cell lung cancer (NSCLC), profoundly ushering in a new treatment landscape. However, both adaptive signaling and oncogenic (epidermal growth factor receptor (EGFR)-driven) signaling may induce PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Anqi, Wei, Ting, Meng, Hui, Luo, Peng, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745797/
https://www.ncbi.nlm.nih.gov/pubmed/31526368
http://dx.doi.org/10.1186/s12943-019-1062-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745797/
https://www.ncbi.nlm.nih.gov/pubmed/31526368
http://dx.doi.org/10.1186/s12943-019-1062-7

Ejemplares similares